

Special Issue

Electrochemotherapy as Treatment for Head and Neck Tumors

Message from the Guest Editors

Electrochemotherapy is a treatment combining a low dose of antineoplastic drug (bleomycin) and an electrical pulse (electroporation) applied directly to the cancer cells using an electrode. Electroporation consists of the application of short, intense, pulsed electric fields to tumor cells, with a transient increase of membrane permeability, facilitating cellular uptake of cytotoxic agents and increasing their toxicity.

Electrochemotherapy is indicated for the local treatment of solid tumors; it is a well-established antitumor strategy for cutaneous neoplasms and has interesting applications for the treatment of head and neck tumors. In fact, it is effective with any tumor regardless of the histotype and has several mechanisms of action with vascular and immunologic effects, ensuring good control of bleeding lesions and interesting prospects for the general care of cancer patients. The interest in electrochemotherapy for the treatment of tumors in the head and neck area has increased because it results in minimal or no impacts to function and can lead to healing of treated tumor lesions without damage to the healthy tissues.

Guest Editors

Dr. Francesco Longo

Dr. Barbara Pichi

Dr. Francesco Perri

Deadline for manuscript submissions

closed (30 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/49690

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)